Skip to Main content Skip to Navigation
Journal articles

Geographic differences in heart failure trials

Abstract : Randomized controlled trials (RCTs) are essential to develop advances in heart failure (HF). The need for increasing numbers of patients (without substantial cost increase) and generalization of results led to the disappearance of international boundaries in large RCTs. The significant geographic differences in patients' characteristics, outcomes, and, most importantly, treatment effect observed in HF trials have recently been highlighted. Whether the observed regional discrepancies in HF trials are due to trial-specific issues, patient heterogeneity, structural differences in countries, or a complex interaction between factors are the questions we propose to debate in this review. To do so, we will analyse and review data from HF trials conducted in different world regions, from heart failure with preserved ejection fraction (HF-PEF), heart failure with reduced ejection fraction (HF-REF), and acute heart failure (AHF). Finally, we will suggest objective and actionable measures in order to mitigate regional discrepancies in future trials, particularly in HF-PEF where prognostic modifying treatments are urgently needed and in which trials are more prone to selection bias, due to a larger patient heterogeneity.
Complete list of metadata
Contributor : DCAC UL Connect in order to contact the contributor
Submitted on : Wednesday, March 28, 2018 - 12:28:41 PM
Last modification on : Thursday, July 14, 2022 - 5:16:29 PM

Links full text




Joao Pedro Ferreira, Nicolas Girerd, Patrick Rossignol, Faiez Zannad. Geographic differences in heart failure trials. European Journal of Heart Failure, European Society of Cardiology (Wiley), 2015, 17 (9), pp.893 - 905. ⟨10.1002/ejhf.326⟩. ⟨hal-01745546⟩



Record views